• +1-646-491-9876
    • +91-20-67278686

    Search

    Hyperuricemia - Pipeline Review, H1 2017

    Hyperuricemia - Pipeline Review, H1 2017

    • Report Code ID: RW0001767477
    • Category Pharmaceuticals
    • No. of Pages 63
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Hyperuricemia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H1 2017, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.

    High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones) , or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

    Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Hyperuricemia - Overview
    Hyperuricemia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Hyperuricemia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Hyperuricemia - Companies Involved in Therapeutics Development
    Allena Pharmaceuticals Inc
    AstraZeneca Plc
    CymaBay Therapeutics Inc
    Jiangsu Hengrui Medicine Co Ltd
    Nippon Chemiphar Co Ltd
    Nobelpharma Co Ltd
    Polaris Pharmaceuticals Inc
    Teijin Pharma Ltd
    Hyperuricemia - Drug Profiles
    (allopurinol + lesinurad) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ALLN-346 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    arhalofenate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    febuxostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FYU-981 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HSA-Uricase - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JPH-367 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NC-2500 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NC-2700 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NPCX-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegadricase - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SHR-4640 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TMX-049 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    verinurad - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hyperuricemia - Dormant Projects
    Hyperuricemia - Discontinued Products
    Hyperuricemia - Product Development Milestones
    Featured News & Press Releases
    Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat
    Jan 04, 2017: Ironwood Announces New Drug Application for DUZALLO (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review
    Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit
    Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricemia and Predicts Savings for NHS Scotland
    May 23, 2016: Teijin Pharma's Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia
    Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11
    Jun 30, 2015: New Indication for Teijin Pharma's Febuxostat in Europe
    Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat
    Nov 05, 2013: Teijin Pharma files patent infringement suit against Dr Reddy's
    Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric
    Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat
    Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat
    Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea
    May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan
    Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Hyperuricemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hyperuricemia - Pipeline by Allena Pharmaceuticals Inc, H1 2017
    Hyperuricemia - Pipeline by AstraZeneca Plc, H1 2017
    Hyperuricemia - Pipeline by CymaBay Therapeutics Inc, H1 2017
    Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
    Hyperuricemia - Pipeline by Nippon Chemiphar Co Ltd, H1 2017
    Hyperuricemia - Pipeline by Nobelpharma Co Ltd, H1 2017
    Hyperuricemia - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
    Hyperuricemia - Pipeline by Teijin Pharma Ltd, H1 2017
    Hyperuricemia - Dormant Projects, H1 2017
    Hyperuricemia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Hyperuricemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Allena Pharmaceuticals Inc
    AstraZeneca Plc
    CymaBay Therapeutics Inc
    Jiangsu Hengrui Medicine Co Ltd
    Nippon Chemiphar Co Ltd
    Nobelpharma Co Ltd
    Polaris Pharmaceuticals Inc
    Teijin Pharma Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//hyperuricemia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hyperuricemia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hyperuricemia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments